Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy

被引：0
|
作者：
Butaney, Mohit
Porter, Jennifer
Lindeman, Neal Ian
Janne, Pasi A.
Rabin, Michael S.
Marcoux, J. Paul
Johnson, Bruce E.
Jackman, David Michael
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
    Kim, Seung Tae
    Lim, Do Hyoung
    Jang, Kee-Taek
    Lim, Taekyu
    Lee, Jeeyun
    Choi, Yoon-La
    Jang, Hye-Lim
    Yi, Jun Ho
    Baek, Kyung Kee
    Park, Se Hoon
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Joon Oh
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (10) : 1993 - 1999
  • [2] Impact of somatic KRAS Mutations on the First-line Therapy in Pancreatic Cancer
    Bochum, S.
    Vladimirova, D.
    Akkad, J.
    Weiss, M.
    Martens, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 224 - 224
  • [3] Impact of the first-line treatment on the clinical course in Japanese NSCLC patients with EGFR mutations.
    Sakamori, Yuichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy
    Jinpeng Shi
    Hui Yang
    Tao Jiang
    Xuefei Li
    Chao Zhao
    Limin Zhang
    Sha Zhao
    Xiaozhen Liu
    Yijun Jia
    Yan Wang
    Lei Xi
    Shijia Zhang
    Chunxia Su
    Shengxiang Ren
    Caicun Zhou
    Chinese Journal of Cancer Research, 2017, 29 (06) : 543 - 552
  • [5] Optimal first-line therapy for NSCLC with EGFR mutations
    Joel W. Neal
    Lecia V. Sequist
    Nature Reviews Clinical Oncology, 2010, 7 : 71 - 72
  • [6] OUTCOMES FOLLOWING FIRST-LINE IMMUNOTHERAPY WITH OR WITHOUT CHEMOTHERAPY STRATIFIED BY KRAS MUTATIONAL STATUS - A REAL WORLD ANALYSIS IN PATIENTS WITH ADVANCED NSCLC
    Aggarwal, Charu
    Nimeiri, Halla
    Chen, James
    Huerga, Iker
    Horn, Leora
    Trunova, Nataliya
    Patel, Jyoti
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1458 - A1458
  • [7] First-line chemotherapy for NSCLC: an overview of relevant trials
    Belani, CP
    Langer, C
    LUNG CANCER, 2002, 38 : S13 - S19
  • [8] Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2012, 13 (03): : 225 - 227
  • [9] Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
    Sun, Yingjia
    Li, Ziming
    Jian, Hong
    Xia, Liliang
    Lu, Shun
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [10] KRAS MUTATIONS AND OUTCOME IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CETUXIMAB
    Tejpar, Sabine
    Bokemeyer, Carsten
    Celik, Ilhan
    Schlichting, Michael
    Heeger, Steffen
    Van Cutsem, Eric
    ANNALS OF ONCOLOGY, 2011, 22 : v16 - v17
12345